Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 References

Enarodustat

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Enarodustat
Clinical data

Trade names	Enaroy
Other names	JTZ-951
Legal status
Legal status	Rx-only (Japan)
Identifiers
IUPAC name 2-{[7-Hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]formamido}acetic acid
CAS Number	1262132-81-9
PubChem CID	50899324
DrugBank	14985
ChemSpider	64835234
UNII	JSK7TUA223
KEGG	D11523
ChEMBL	ChEMBL4297619
Chemical and physical data
Formula	C₁₇H₁₆N₄O₄
Molar mass	340.339 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
InChI InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24) Key:FJYRBJKWDXVHHO-UHFFFAOYSA-N

Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH).^[1]

The drug was approved in September 2020 in Japan for anemia associated with CKD^[2] and is currently in clinical development in the United States and South Korea.^[3] The drug is being developed by Japan Tobacco and JW Pharmaceutical.^[4]

References[edit]

^ Hirota K (April 2021). "HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review". Biomedicines. 9 (5): 468. doi:10.3390/biomedicines9050468. PMC 8146675. PMID 33923349.

^ "JT Receives Manufacturing and Marketing Approval of ENAROY Tablets 2mg・4mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan" (PDF) (Press release). September 25, 2020.

^ Markham A (January 2021). "Enarodustat: First Approval". Drugs. 81 (1): 169–174. doi:10.1007/s40265-020-01444-3. PMID 33320297. S2CID 229163684.

^ "Enarodustat - Japan Tobacco". Adis Insight.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Enarodustat&oldid=1175852490" Categories: ●Drugs acting on the blood and blood forming organs ●Alpha-Amino acids ●Triazolopyridines ●Secondary amino acids ●Blood and blood forming organ drug stubs Hidden categories: ●Articles with short description ●Short description matches Wikidata ●Drugs with non-standard legal status ●Infobox drug articles with non-default infobox title ●Drugs missing an ATC code ●Articles containing unverified chemical infoboxes ●All stub articles ●This page was last edited on 17 September 2023, at 21:27 (UTC). ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization. ●Privacy policy ●About Wikipedia ●Disclaimers ●Contact Wikipedia ●Code of Conduct ●Developers ●Statistics ●Cookie statement ●Mobile view